Synergy of purine-scaffold TLR7 agonist with doxorubicin on systemic inhibition of lymphoma in mouse model.

about

Synergy of purine-scaffold TLR7 agonist with doxorubicin on systemic inhibition of lymphoma in mouse model.

Item

http://www.wikidata.org/entity/Q47135118

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Synergy of purine-scaffold TLR ...... on of lymphoma in mouse model.

@en

Synergy of purine-scaffold TLR ...... on of lymphoma in mouse model.

@nl

type

Item

label

Synergy of purine-scaffold TLR ...... on of lymphoma in mouse model.

@en

Synergy of purine-scaffold TLR ...... on of lymphoma in mouse model.

@nl

prefLabel

Synergy of purine-scaffold TLR ...... on of lymphoma in mouse model.

@en

Synergy of purine-scaffold TLR ...... on of lymphoma in mouse model.

@nl

P1476

Synergy of purine-scaffold TLR ...... on of lymphoma in mouse model.

@en

P2093

Chih-Chang Wei

http://www.w3.org/2001/XMLSchema#string

Dong Gao

http://www.w3.org/2001/XMLSchema#string

Wang Li

http://www.w3.org/2001/XMLSchema#string

Wanmin Wang

http://www.w3.org/2001/XMLSchema#string

Xiaoling Luo

http://www.w3.org/2001/XMLSchema#string

Yongguang Cai

http://www.w3.org/2001/XMLSchema#string

Yuhuan Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Imiquimod applied topically: a novel immune response modifier and new class of drug

Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Differential induction of interleukin-10 and interleukin-12 in dendritic cells by microbial toll-like receptor activators and skewing of T-cell cytokine profiles.

Rituximab resistance.

Recombinant toxins for the treatment of cancer.

Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7.

P304

3183-3189

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/JCA.20015

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29158790

http://www.w3.org/2001/XMLSchema#string

P932

5665034

http://www.w3.org/2001/XMLSchema#string